A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection

PHASE1CompletedINTERVENTIONAL
Enrollment

261

Participants

Timeline

Start Date

June 24, 2019

Primary Completion Date

March 4, 2021

Study Completion Date

November 6, 2023

Conditions
Melanoma
Interventions
DRUG

Nivolumab

Specified dose on specified days

Trial Locations (37)

0

Local Institution - 0022, Santiago

Local Institution - 0004, Christchurch

1023

Local Institution - 0005, Auckland

1431

Local Institution - 0046, Buenos Aires

2065

Local Institution - 0001, Wollstonecraft

6021

Local Institution - 0003, Wellington

13385

Local Institution - 0009, Marseille

14080

Local Institution - 0034, Tlalpan

15213

Local Institution - 0043, Pittsburgh

24127

Local Institution - 0014, Bergamo

28007

Local Institution - 0026, Madrid

28040

Local Institution - 0027, Madrid

28204

Local Institution - 0035, Charlotte

29010

Local Institution - 0028, Málaga

35128

Local Institution - 0015, Padua

44093

Local Institution - 0010, Nantes

53100

Local Institution - 0016, Siena

55407

Local Institution - 0008, Minneapolis

64460

Local Institution - 0033, Monterrey

66278

Local Institution - 0031, San Pedro Garza García

75475

Local Institution - 0011, Paris

300696

Local Institution - 0030, Timișoara

8420383

Local Institution - 0045, Santiago

15090000

Local Institution - 0040, São José do Rio Preto

06106

Local Institution - 0006, Hartford

98700-000

Local Institution - 0036, Ijuí

90610-000

Local Institution - 0037, Porto Alegre

14780-070

Local Institution - 0039, Barretos

01246-000

Local Institution - 0038, Cerqueira César

20230-130

Local Institution - 0041, Rio de Janeiro

T6X 1E8

Local Institution - 0013, Edmonton

Unknown

Local Institution - 0024, Independencia

Local Institution - 0023, Santiago

Local Institution - 0032, Dublin

T12 DC4A

Local Institution - 0018, Wilton

02-781

Local Institution - 0017, Warsaw

08916

Local Institution - 0029, Badalona-barcelona

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT03980314 - A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection | Biotech Hunter | Biotech Hunter